PLoS Medicine (Nov 2017)

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

  • Nathan W Cummins,
  • Stacey Rizza,
  • Mark R Litzow,
  • Stephane Hua,
  • Guinevere Q Lee,
  • Kevin Einkauf,
  • Tae-Wook Chun,
  • Frank Rhame,
  • Jason V Baker,
  • Michael P Busch,
  • Nicolas Chomont,
  • Patrick G Dean,
  • Rémi Fromentin,
  • Ashley T Haase,
  • Dylan Hampton,
  • Sheila M Keating,
  • Steven M Lada,
  • Tzong-Hae Lee,
  • Sekar Natesampillai,
  • Douglas D Richman,
  • Timothy W Schacker,
  • Stephen Wietgrefe,
  • Xu G Yu,
  • Joseph D Yao,
  • John Zeuli,
  • Mathias Lichterfeld,
  • Andrew D Badley

DOI
https://doi.org/10.1371/journal.pmed.1002461
Journal volume & issue
Vol. 14, no. 11
p. e1002461

Abstract

Read online

BACKGROUND:Notwithstanding 1 documented case of HIV-1 cure following allogeneic stem cell transplantation (allo-SCT), several subsequent cases of allo-SCT in HIV-1 positive individuals have failed to cure HIV-1 infection. The aim of our study was to describe changes in the HIV reservoir in a single chronically HIV-infected patient on suppressive antiretroviral therapy who underwent allo-SCT for treatment of acute lymphoblastic leukemia. METHODS AND FINDINGS:We prospectively collected peripheral blood mononuclear cells (PBMCs) by leukapheresis from a 55-year-old man with chronic HIV infection before and after allo-SCT to measure the size of the HIV-1 reservoir and characterize viral phylogeny and phenotypic changes in immune cells. At day 784 post-transplant, when HIV-1 was undetectable by multiple measures-including PCR measurements of both total and integrated HIV-1 DNA, replication-competent virus measurement by large cell input quantitative viral outgrowth assay, and in situ hybridization of colon tissue-the patient consented to an analytic treatment interruption (ATI) with frequent clinical monitoring. He remained aviremic off antiretroviral therapy until ATI day 288, when a low-level virus rebound of 60 HIV-1 copies/ml occurred, which increased to 1,640 HIV-1 copies/ml 5 days later, prompting reinitiation of ART. Rebounding plasma HIV-1 sequences were phylogenetically distinct from proviral HIV-1 DNA detected in circulating PBMCs before transplantation. The main limitations of this study are the insensitivity of reservoir measurements, and the fact that it describes a single case. CONCLUSIONS:allo-SCT led to a significant reduction in the size of the HIV-1 reservoir and a >9-month-long ART-free remission from HIV-1 replication. Phylogenetic analyses suggest that the origin of rebound virus was distinct from the viruses identified pre-transplant in the PBMCs.